
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with...
Oral Therapy MZE001 Well-tolerated in Healthy Volunteers in Trial
Maze planning Phase 2 study of substrate reduction therapy in 2023
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
Make A Donation
